Trastuzumab deruxtecan - Daiichi Sankyo

Drug Profile

Trastuzumab deruxtecan - Daiichi Sankyo

Alternative Names: DS-8201; DS-8201a

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Bristol-Myers Squibb; Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Uterine cancer
  • Phase I Solid tumours; Urogenital cancer

Most Recent Events

  • 20 Jun 2018 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03523572)
  • 20 Jun 2018 Phase-I clinical trials in Urogenital cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03523572)
  • 01 Jun 2018 Efficacy and adverse events data from a phase I trial HER2-expressing Breast, gastric and solid cancers presented at the Annual Meeting of American Society of Clinical Oncology (ASCO 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top